TABLE OF CONTENTS

1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL INJECTABLEDRUG DELIVERY MARKET

1.2. CURRENCY AND PRICING

1.3. LIMITATION

1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED

2.2. GEOGRAPHIC SCOPE

2.3. YEARS CONSIDERED FOR THE STUDY

2.4. CURRENCY AND PRICING

2.5. RESEARCH METHODOLOGY

2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7. SECONDARY SOURCES

2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES

3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES

3.1.3. GROWTH OF BIOLOGICS MARKET

3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. NEEDLESTICK INJURIES AND INFECTIONS

3.2.2. HIGH COST OF DEVELOPMENT

3.2.3. STRICT REGULATORY FRAMEWORK

3.3. OPPORTUNITY

3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS

3.3.1.1. GENERICS

3.3.1.2. BIOSIMILARS

3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES

3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION

3.4.2. PRODUCT RECALL

3.4.3. STABILITY OF PRODUCTS

3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY

6.1. OVERVIEW

6.2. U.S. FDA APPROVAL

6.3. CE MARKING (EUROPEAN CONFORMITY)

6.4. EM (EUROPEAN MEDICINE AGENCY)

7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

7.1. OVERVIEW

7.2. INJECTABLE DRUG DELIVERY DEVICES

7.2.1. CONVENTIONAL INJECTION DEVICES

7.2.2. SELF INJECTION DEVICES

7.2.2.1. NEEDLE FREE INJECTORS (NFI)

7.2.2.2. AUTO INJECTORS

7.2.2.3. PEN INJECTORS

7.2.2.4. WEARABLE INJECTORS

7.3. INJECTABLE DRUG DELIVERY FORMULATION

7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.1. SOLUTIONS

7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS

7.3.1.3. SUSPENSIONS

7.3.1.4. EMULSIONS

7.3.2. NOVEL DRUG DELIVERY FORMULATIONS

7.3.2.1. COLLOIDAL DISPERSIONS

7.3.2.2. MICROPARTICLES

7.3.2.3. LONG ACTING INJECTION FORMULATION

8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.1. OVERVIEW

8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.3. HORMONAL DISORDERS

8.3.1. INJECTABLE DRUGS FOR DIABETES

8.3.2. INJECTABLE DRUGS FOR ANEMIA

8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE

8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY

8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS

8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

8.4. ONCOLOGY

8.5. AUTOIMMUNE DISEASES

8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS

8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS

8.5.3. INJECTABLE DRUGS FOR CROHN’S DISEASES

8.5.4. INJECTABLE DRUGS FOR PSORIASIS

8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

8.6. ORPHAN DISEASE

8.7. OTHER APPLICATIONS

8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT

8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT

8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS

8.7.4. INJECTABLE DRUGS FOR HEPATITIS C

8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

9.1. OVERVIEW

9.2. CURATIVE CARE

9.3. IMMUNIZATIONS

9.4. OTHER USAGE PATTERN

10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

10.1. OVERVIEW

10.2. SKIN

10.3. CIRCULATORY/ MUSKOSKELETAL

10.4. ORGANS

10.5. CENTRAL NERVOUS SYSTEM

11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1. OVERVIEW

11.2. HOSPITALS AND CLINICS

11.3. HOME HEALTHCARE SETTINGS

11.4. RESEARCH LABORATORIES

11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES

11.6. OTHER END USERS

12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

12.1. OVERVIEW

12.1.1. HOSPITAL PHARMACY

12.1.2. PHARMACY STORES

12.1.3. DIRECT TENDER

12.1.4. ONLINE PHARMACY

13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. OVERVIEW

13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.2.1. U.S. INJECTABLE DRUG DELIVERY MARKET

13.2.2. CANADA INJECTABLE DRUG DELIVERY MARKET

13.2.3. MEXICO INJECTABLE DRUG DELIVERY MARKET

13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET

13.3.1. GERMANY INJECTABLE DRUG DELIVERY MARKET

13.3.2. FRANCE INJECTABLE DRUG DELIVERY MARKET

13.3.3. UK INJECTABLE DRUG DELIVERY MARKET

13.3.4. ITALY INJECTABLE DRUG DELIVERY MARKET

13.3.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET

13.3.6. SPAIN INJECTABLE DRUG DELIVERY MARKET

13.3.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET

13.3.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET

13.3.9. TURKEY INJECTABLE DRUG DELIVERY MARKET

13.3.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET

13.3.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET

13.4. APAC INJECTABLE DRUG DELIVERY MARKET

13.4.1. JAPAN INJECTABLE DRUG DELIVERY MARKET

13.4.2. CHINA INJECTABLE DRUG DELIVERY MARKET

13.4.3. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET

13.4.4. INDIA INJECTABLE DRUG DELIVERY MARKET

13.4.5. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET

13.4.6. SINGAPORE INJECTABLE DRUG DELIVERY MARKET

13.4.7. THAILAND INJECTABLE DRUG DELIVERY MARKET

13.4.8. MALAYSIA INJECTABLE DRUG DELIVERY MARKET

13.4.9. INDONESIA INJECTABLE DRUG DELIVERY MARKET

13.4.10. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET

13.4.11. REST OF APAC INJECTABLE DRUG DELIVERY MARKET

13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.5.1. BRAZIL INJECTABLE DRUG DELIVERY MARKET

13.5.2. REST OF SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.6. MEA INJECTABLE DRUG DELIVERY MARKET

13.6.1. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET

13.6.2. REST OF MEA INJECTABLE DRUG DELIVERY MARKET

14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

14.1. COMPANY SHARE ANALYSIS: GLOBAL

15. COMPANY PROFILES

15.1. BECTON, DICKINSON AND COMPANY

15.1.1. COMPANY OVERVIEW

15.1.1.1. DRIVERS EXPLAINED

15.1.1.2. WEAKNESSES EXPLAINED

15.1.1.3. OPPURTUNITIES EXPLAINED

15.1.1.4. THREATS EXPLAINED

15.1.2. PRODUCT PORTFOLIO

15.1.3. RECENT DEVELOPMENTS

15.2. PFIZER

15.2.1. COMPANY OVERVIEW

15.2.1.1. DRIVERS EXPLAINED

15.2.1.2. WEAKNESSES EXPLAINED

15.2.1.3. OPPURTUNITIES EXPLAINED

15.2.1.4. THREATS EXPLAINED

15.2.2. PRODUCT PORTFOLIO

15.2.3. RECENT DEVELOPMENTS

15.3. BAXTER INTERNATIONAL

15.3.1. COMPANY OVERVIEW

15.3.1.1. DRIVERS EXPLAINED

15.3.1.2. WEAKNESSES EXPLAINED

15.3.1.3. OPPURTUNITIES EXPLAINED

15.3.1.4. THREATS EXPLAINED

15.3.2. PRODUCT PORTFOLIO

15.3.3. RECENT DEVELOPMENTS

15.4. GERRESHEIMER AG

15.4.1. COMPANY OVERVIEW

15.4.2. PRODUCT PORTFOLIO

15.4.3. RECENT DEVELOPMENTS

15.5. SCHOTT AG INC.

15.5.1. COMPANY OVERVIEW

15.5.2. PRODUCT PORTFOLIO

15.5.3. RECENT DEVELOPMENTS

15.6. ALKERMES INC.

15.6.1. COMPANY OVERVIEW

15.6.2. PRODUCT PORTFOLIO

15.6.3. RECENT DEVELOPMENTS

15.7. ANTARES PHARMA

15.7.1. COMPANY OVERVIEW

15.7.2. PRODUCT PORTFOLIO

15.7.3. RECENT DEVELOPMENTS

15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)

15.8.1. COMPANY OVERVIEW

15.8.2. PRODUCT PORTFOLIO

15.8.3. RECENT DEVELOPMENTS

15.9. ELCAM MEDICAL

15.9.1. COMPANY OVERVIEW

15.9.2. PRODUCT PORTFOLIO

15.9.3. RECENT DEVELOPMENTS

15.10. ELI LILLY AND COMPANY

15.10.1. COMPANY OVERVIEW

15.10.1.1. DRIVERS EXPLAINED

15.10.1.2. WEAKNESSES EXPLAINED

15.10.1.3. OPPURTUNITIES EXPLAINED

15.10.1.4. THREATS EXPLAINED

15.10.2. PRODUCT PORTFOLIO

15.10.3. RECENT DEVELOPMENTS

15.11. HASELMEIER

15.11.1. COMPANY OVERVIEW

15.11.2. PRODUCT PORTFOLIO

15.11.3. RECENT DEVELOPMENTS

15.12. MYLAN N.V.

15.12.1. COMPANY OVERVIEW

15.12.2. PRODUCT PORTFOLIO

15.12.3. RECENT DEVELOPMENTS

15.13. NOVO NORDISK

15.13.1. COMPANY OVERVIEW

15.13.2. PRODUCT PORTFOLIO

15.13.3. RECENT DEVELOPMENTS

15.14. OWEN MUMFORD LTD

15.14.1. COMPANY OVERVIEW

15.14.2. PRODUCT PORTFOLIO

15.14.3. RECENT DEVELOPMENTS

15.15. SANDOZ INTERNATIONAL GMBH

15.15.1. COMPANY OVERVIEW

15.15.2. PRODUCT PORTFOLIO

15.15.3. RECENT DEVELOPMENTS

15.16. SANOFI

15.16.1. COMPANY OVERVIEW

15.16.2. PRODUCT PORTFOLIO

15.16.3. RECENT DEVELOPMENTS

15.17. TERUMO CORPORATION

15.17.1. COMPANY OVERVIEW

15.17.2. PRODUCT PORTFOLIO

15.17.3. RECENT DEVELOPMENTS

15.18. TEVA PHARMACEUTICAL

15.18.1. COMPANY OVERVIEW

15.18.1.1. DRIVERS EXPLAINED

15.18.1.2. WEAKNESSES EXPLAINED

15.18.1.3. OPPURTUNITIES EXPLAINED

15.18.1.4. THREATS EXPLAINED

15.18.2. PRODUCT PORTFOLIO

15.18.3. RECENT DEVELOPMENTS

15.19. WEST PHARMACEUTICAL SERVICES, INC

15.19.1. COMPANY OVERVIEW

15.19.2. PRODUCT PORTFOLIO

15.19.3. RECENT DEVELOPMENTS

15.20. YPSOMED HOLDING AG

15.20.1. COMPANY OVERVIEW

15.20.2. PRODUCT PORTFOLIO

15.20.3. RECENT DEVELOPMENTS

16. RELATED REPORTS

TABLE LIST

TABLE 1 EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS ()(2013- 2017)

TABLE 2 NUMBER OF NEEDLESTICK INJURIES

TABLE 3 LIST OF PRODUCT RECALL DRUGS

TABLE 4 LIST OF DIFFERENT TYPES OF APPROVAL FOR DIFFERENT COUNTRIES

TABLE 5 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 6 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 7 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY MATERIAL, 2015 – 2024 (USD MILLION)

TABLE 8 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

TABLE 9 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)

TABLE 10 GLOBAL SELF INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 11 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

TABLE 12 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 13 GLOBAL NEEDLE FREE INJECTORS DEVICE ARKET, BY USABILITY, 2015 – 2024 (USD MILLION)

TABLE 14 GLOBAL AUTO INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

TABLE 15 GLOBAL AUTO INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 16 GLOBAL AUTO INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)

TABLE 17 GLOBAL AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)

TABLE 18 GLOBAL PEN INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

TABLE 19 GLOBAL PEN INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024 (USD MILLION)

TABLE 20 GLOBAL PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)

TABLE 21 GLOBAL INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 22 LIST OF SOME OF THE LYOPHILIZED FORMULATIONS

TABLE 23 LIST OF SOME OF THE EMULSIONS

TABLE 24 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 25 GLOBAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE,2015 – 2024 (USD MILLION)

TABLE 26 GLOBAL COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 27 LIST OF SOME OF THE NIOSOMES

TABLE 28 LIST OF SOME OF THE POLYMERIC MIXED MICELLES DRUG MANUFACTURER

TABLE 29 LIST OF NANOSUSPENSION DRUG MANUFACTURER

TABLE 30 LIST OF SOME OF THE NANOEMULSIONS/MICROEMULSIONS DRUG MANUFACTURER

TABLE 31 LIST OF SOME OF THE SOLID LIPID NANOPARTICLES DRUG MANUFACTURER

TABLE 32 GLOBAL NANOPARTICLE COLLOIDAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

TABLE 33 LIST OF SOME OF THE MICROSPHERES DRUG MANUFACTURER

TABLE 34 GLOBAL MICROPARTICLES COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 35 LIST OF SOME OF THE FIRST GENERATION LONG ACTING INJECTION

TABLE 36 LIST OF SOME OF THE SECOND GENERATION LONG ACTING INJECTION:

TABLE 37 GLOBAL INJECTABLE DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 38 GLOBAL HORMONAL DISORDERS INJECTABLE DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)

TABLE 39 GLOBAL AUTOIMMUNE DISEASE INJECTABLE DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)

TABLE 40 LIST OF ORPHAN DISEASE IN INDIA (2010)

TABLE 41 GLOBAL OTHERS INJECTABLE DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)

TABLE 42 GLOBALINJECTABLE DRUG DELIVERY USAGE PATTERN MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 43 GLOBAL INJECTABLE DRUG DELIVERY MODE OF ADMINISTRATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

TABLE 44 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 45 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)

TABLE 46 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION)

TABLE 47 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)

TABLE 48 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 49 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 50 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY MATERIAL,2015 – 2024(USD MILLION)

TABLE 51 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

TABLE 52 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 53 NORTH AMERICA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 54 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT,2015 – 2024(USD MILLION)

TABLE 55 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 56 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 57 NORTH AMERICA AUTO INJECTORSDEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 58 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 59 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 60 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 61 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 62 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 63 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 64 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

TABLE 65 NORTH AMERICA CONVENTIONALDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 66 NORTH AMERICA NOVELDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 67 NORTH AMERICA COLLOIDALDISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 68 NORTH AMERICA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 69 NORTH AMERICA MICROPARTICLESDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 70 NORTH AMERICAINJECTABLE DRUG DELIVERY MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)

TABLE 71 NORTH AMERICA AUTOIMMUNE DISEASES INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 72 NORTH AMERICA HORMONAL DISORDERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 73 NORTH AMERICA OTHERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 74 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)

TABLE 75 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)

TABLE 76 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 77 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)

TABLE 78 U.S. INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 79 U.S. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 80 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)

TABLE 81 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

TABLE 82 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 83 U.S. SELF INJECTION DEVICE MARKET, BY TYPE,2015 – 2024(USD MILLION)

TABLE 84 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 85 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 86 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 87 U.S. AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 88 U.S. AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 89 U.S. AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 90 U.S. AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 91 U.S. PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 92 U.S. PEN INJECTORS DEVICE MARKET, BY DESIGN,2015 – 2024(USD MILLION)

TABLE 93 U.S. PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 94 U.S. INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

TABLE 95 U.S. CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 96 U.S. NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 97 U.S. COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 98 U.S. NANOPARTICLES COLLOIDAL DISPERSIONS NOVELDRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 99 U.S. MICROPARTICLES NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 100 U.S. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 101 U.S. AUTOIMMUNE DISEASES INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 102 U.S. HORMONAL DISORDERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 103 U.S. OTHERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 104 U.S. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)

TABLE 105 U.S. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)

TABLE 106 U.S. INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 107 U.S. INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)

TABLE 108 CANADA INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 109 CANADA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 110 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)

TABLE 111 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

TABLE 112 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 113 CANADA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 114 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 115 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 116 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 117 CANADA AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 118 CANADA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 119 CANADA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 120 CANADA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 121 CANADA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 122 CANADA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 123 CANADA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 124 CANADA INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

TABLE 125 CANADA CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 126 CANADA NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 127 CANADA COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 128 CANADA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 129 CANADA MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 130 CANADA INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 131 CANADA AUTOIMMUNE DISEASES INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 132 CANADA HORMONAL DISORDERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 133 CANADA OTHERS INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

TABLE 134 CANADA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)

TABLE 135 CANADA INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)

TABLE 136 CANADA INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)

TABLE 137 CANADA INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)

TABLE 138 MEXICO INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 139 MEXICO INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 140 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)

TABLE 141 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

TABLE 142 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 143 MEXICO SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)

TABLE 144 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 145 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 146 MEXICO NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 147 MEXICO AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 148 MEXICO AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

TABLE 149 MEXICO AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 150 MEXICO AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 151 MEXICO PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

TABLE 152 MEXICO PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

TABLE 153 MEXICO PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

TABLE 154 MEXICO INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

TABLE 155 MEXICO CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 156 MEXICO NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 157 MEXICO COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

TABLE 158 MEXICO NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

TABLE 159 MEXICO MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

FIGURES LIST

FIGURE 1 GLOBAL INJECTABLE DRUG DELIVERY MARKET: SEGMENTATION

FIGURE 2 GLOBAL INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SCOPE

FIGURE 3 GLOBAL INJECTABLE DRUG DELIVERY MARKET: DATA TRIANGULATION

FIGURE 4 GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

FIGURE 5 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BOTTOM UP APPROACH

FIGURE 6 GLOBAL INJECTABLE DRUG DELIVERY MARKET: TOP DOWN APPROACH

FIGURE 7 GLOBAL INJECTABLE DRUG DELIVERY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 FIGURE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTABLE DRUG DELIVERY MARKET

FIGURE 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR INJECTABLE DRUG DELIVERY IN 2016 AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD TO 2024

FIGURE 10 TECHNOLOGICAL DEVELOPMENT AND INCREASING PREVALENCE OF CHRONIC DISEASES ARE EXPECTED TO DRIVE THE MARKET FOR INJECTABLE DRUG DELIVERY IN THE FORECAST PERIOD 2017 TO 2024

FIGURE 11 INJECTABLE DRUG DELIVERY FORMULATION MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET IN 2017 & 2024

FIGURE 12 NORTH AMERICA IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR INJECTABLE DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD TO 2024

FIGURE 13 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BY TYPE, SNAPSHOT 2016

FIGURE 14 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BY APPLICATION, SNAPSHOT 2016

FIGURE 15 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BY USAGE PATTERN, SNAPSHOT 2016

FIGURE 16 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BY MODE OF ADMINISTRATION, SNAPSHOT 2016

FIGURE 17 GLOBAL INJECTABLE DRUG DELIVERY MARKET DOMINATED BY HOSPITAL AND CLIINICS SEGMENT

FIGURE 18 GLOBAL INJECTABLE DRUG DELIVERYMARKET:BY END-USER, SNAPSHOT 2016

FIGURE 19 GLOBAL INJECTABLE DRUG DELIVERY MARKET: BY DISTRIBUTION CHANNEL, SNAPSHOT 2016

FIGURE 20 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2017)

FIGURE 21 EUROPEAN INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2017)

FIGURE 22 ASIA GLOBAL INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2017)

FIGURE 23 SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2017)

FIGURE 24 MEA GLOBAL INJECTABLE DRUG DELIVERY MARKET SNAPSHOT (2017)

FIGURE 25 GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%)

FIGURE 26 BECTON, DICKINSON AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

FIGURE 27 BECTON, DICKINSOM AND COMPANY: REVENUE ANALYSIS

FIGURE 28 PFIZER, INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

FIGURE 29 PFIZER, INC.: REVENUE ANALYSIS

FIGURE 30 BAXTER INTERNATIONAL INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

FIGURE 31 BAXTER INTERNATIONAL, INC.: REVENUE ANALYSIS

FIGURE 32 GERRESHEIMER AG: REVENUE ANALYSIS

FIGURE 33 SCHOTT AG INC.: REVENUE ANALYSIS

FIGURE 34 ALKERMES INC.: REVENUE ANALYSIS

FIGURE 35 ANTARES PHARMA: REVENUE ANALYSIS

FIGURE 36 BESPAK: REVENUE ANALYSIS

FIGURE 37 ELCAM MEDICAL: REVENUE ANALYSIS

FIGURE 38 ELI LILLY AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

FIGURE 39 ELI LILLY AND COMPANY: REVENUE ANALYSIS

FIGURE 40 HASELMEIER: REVENUE ANALYSIS

FIGURE 41 MYLAN N.V.: REVENUE ANALYSIS

FIGURE 42 NOVO NORDISK: REVENUE ANALYSIS

FIGURE 43 OWEN MUMFORD LTD: REVENUE ANALYSIS

FIGURE 44 SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS

FIGURE 45 SANOFI: REVENUE ANALYSIS

FIGURE 46 TERUMO CORPORATION: REVENUE ANALYSIS

FIGURE 47 TEVA PHARMACEUTICAL: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

FIGURE 48 TEVA PHARMACEUTICAL: REVENUE ANALYSIS

FIGURE 49 WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS

FIGURE 50 YPSOMED HOLDING AG: REVENUE ANALYSIS